Biosimilars: A 2020 Mid-Year Review

This webinar has ended.


Biologics are the fastest-growing class of therapeutic products in the United States. In 2019, the FDA approved 10 biosimilars a new record. For pharmaceutical companies, this means that competition in the biosimilars space is heating up and creating a new sense of urgency to innovate.

In this webinar, life sciences attorneys John Adkisson, Geoff Biegler, and Jenny Shmuel provided a mid-year update on the current U.S. biosimilars space. Topics that were discussed include recent developments regarding:

  • The U.S. biosimilars market, including approvals and launches
  • FDA announcements and guidance
  • Select court cases and appellate guidance
  • Trends in IPRs

In addition, our hosts discussed how the ongoing COVID-19 pandemic has impacted U.S. biosimilars and how it could continue to do so in the future.

Click the link to download a copy of the webinar slides.

Presenters: John Adkisson, Geoff Biegler, Jenny Shmuel